瑞银指，由于今年新生率回升，而中国飞鹤逾70%的销售都来自第二和第三期的初生婴儿配方奶粉，以及即将推出的生育资助，料公司2025年至2026年的收入会改善，同时上调今年至2026年的每股盈利预测分别3%至13%。China Feihe (06186) rose nearly 3%, as of the deadline, it rose 2.6%, at HK$5.92, with a turnover of 41.3438 million Hong Kong dollars.
According to the Wisdom Financial APP, China Feihe (06186) rose nearly 3%, as of the deadline, it rose 2.6%, at HK$5.92, with a turnover of 41.3438 million Hong Kong dollars.
UBS Group released research reports pointed out that China Feihe's management stated in Beijing last week that sales in the second half of the year are expected to be better than the first half, benefiting from the rising sales trend in the third quarter, and providing guidance for this year's revenue and net margin growth due to a better product mix, at 5% to 10% and over 10% respectively. The bank believes that the company's stock is undervalued compared to other consumer goods listed companies in Hong Kong, raising the target price from HK$5.1 to HK$6.65, with a 'buy' rating.
UBS Group pointed out that due to the increase in the birth rate this year, and over 70% of China Feihe's sales come from the second and third stages of infant formula milk powder, as well as the upcoming fertility subsidies, the company's revenue is expected to improve from 2025 to 2026, with earnings per share forecast raised by 3% to 13% for the years 2021 to 2026.
